Regenxbio's RGX-202 Appears 'Approvable' in Duchenne Muscular Dystrophy, RBC Says

MT Newswires Live11-07

Regenxbio's (RGNX) RGX-202 investigational therapy for Duchenne muscular dystrophy appears "approvable," with safety and function comparable with that of the FDA-approved rival drug from Sarepta Therapeutics (SRPT), RBC Capital Markets said in a Thursday note.

The company continues to target biologics license application submission to the US FDA in Q1 2027, with a potential approval in H2 of the same year, RBC said. Regenxbio also designed a randomized trial to back RGX-202's global submissions, the investment firm added.

In retinal disease, Regenxbio and partner AbbVie (ABBV) are set to release topline data from two trials of surabgene lomparvovec in wet age-related macular degeneration within this quarter, the brokerage said. Regulatory submissions for the product candidate are planned for 2027, RBC noted.

RBC has an outperform rating on Regenxbio, with a $19 price target.

Price: 7.75, Change: +0.37, Percent Change: +4.95

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2681189303?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-11-07 00:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2681189303","market":"nz","top_or_hot":-1,"title":"Regenxbio's RGX-202 Appears 'Approvable' in Duchenne Muscular Dystrophy, RBC Says","media":"MT Newswires Live","content":"<html><body><p> Regenxbio's (RGNX) RGX-202 investigational therapy for Duchenne muscular dystrophy appears \"approvable,\" with safety and function comparable with that of the FDA-approved rival drug from Sarepta <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (SRPT), RBC Capital Markets said in a Thursday note.</p><p>The company continues to target biologics license application submission to the US FDA in Q1 2027, with a potential approval in H2 of the same year, RBC said. Regenxbio also designed a randomized trial to back RGX-202's global submissions, the investment firm added.</p><p>In retinal disease, Regenxbio and partner AbbVie (ABBV) are set to release topline data from two trials of surabgene lomparvovec in wet age-related macular degeneration within this quarter, the brokerage said. Regulatory submissions for the product candidate are planned for 2027, RBC noted.</p><p>RBC has an outperform rating on Regenxbio, with a $19 price target.</p><p>Price: 7.75, Change: +0.37, Percent Change: +4.95</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regenxbio's RGX-202 Appears 'Approvable' in Duchenne Muscular Dystrophy, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegenxbio's RGX-202 Appears 'Approvable' in Duchenne Muscular Dystrophy, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-11-07 00:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Regenxbio's (RGNX) RGX-202 investigational therapy for Duchenne muscular dystrophy appears \"approvable,\" with safety and function comparable with that of the FDA-approved rival drug from Sarepta <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (SRPT), RBC Capital Markets said in a Thursday note.</p><p>The company continues to target biologics license application submission to the US FDA in Q1 2027, with a potential approval in H2 of the same year, RBC said. Regenxbio also designed a randomized trial to back RGX-202's global submissions, the investment firm added.</p><p>In retinal disease, Regenxbio and partner AbbVie (ABBV) are set to release topline data from two trials of surabgene lomparvovec in wet age-related macular degeneration within this quarter, the brokerage said. Regulatory submissions for the product candidate are planned for 2027, RBC noted.</p><p>RBC has an outperform rating on Regenxbio, with a $19 price target.</p><p>Price: 7.75, Change: +0.37, Percent Change: +4.95</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0456855351.SGD","symbol_name":"JPMorgan Funds - Global Equity A (acc) SGD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2681189303","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2681189303","pubTimestamp":1793982275,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Regenxbio's  RGX-202 investigational therapy for Duchenne muscular dystrophy appears \"approvable,\" with safety and function comparable with that of the FDA-approved rival drug from Sarepta Therapeutics , RBC Capital Markets said in a Thursday note.The company continues to target biologics license application submission to the US FDA in Q1 2027, with a potential approval in H2 of the same year, RBC said. Regenxbio also designed a randomized trial to back RGX-202's global submissions, the investment firm added.In retinal disease, Regenxbio and partner AbbVie  are set to release topline data from two trials of surabgene lomparvovec in wet age-related macular degeneration within this quarter, the brokerage said. Regulatory submissions for the product candidate are planned for 2027, RBC noted.RBC has an outperform rating on Regenxbio, with a $19 price target.Price: 7.75, Change: +0.37, Percent Change: +4.95","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0058720904.USD":"联博国际健康护理基金A","JDOC":"JPMORGAN HEALTHCARE LEADERS ETF","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","TRUH":"VanEck Healthcare TruSector ETF","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","BK4534":"瑞士信贷持仓","FTXH":"First Trust Nasdaq Pharmaceuticals ETF","LU1496350171.SGD":"FRANKLIN DIVERSIFIED BALANCED \"A\" (SGDHDG) ACC","ABBV":"艾伯维公司","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","XLV":"健康照护类股ETF-SPDR","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","IE000F7OJYX1.SGD":"RQI GLOBAL \"I\" (SGDHDG) INC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","SRPT":"Sarepta Therapeutics","BK4505":"高瓴资本持仓","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU0859254822.USD":"T ROWE PRICE GLOBAL VALUE EQUITY \"A\" (USD) ACC","IE00B3PB1722.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","GLAM":"Corgi Beauty, Skincare & Aesthetics ETF","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IXJ":"全球医疗业ETF-iShares","FHLC":"Fidelity MSCI Health Care Index","AGNG":"Global X Aging Population ETF","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","IE000MB6IJN5.SGD":"RQI GLOBAL \"I\" (SGD) ACC","BK4550":"红杉资本持仓","BK4588":"碎股","VHT":"Vanguard Health Care ETF","LU0689626769.HKD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (HKD) ACC","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","PPH":"VanEck Pharmaceutical ETF","SRPU":"2倍做多SRPT ETF-Tradr","RGNX":"Regenxbio Inc","LU0861579265.USD":"联博低波幅策略股票基金A","IYH":"iShares U.S. Healthcare ETF","MEDX":"HORIZON KINETICS MEDICAL ETF","LU0234572021.USD":"高盛美国核心股票组合Acc","RXL":"ProShares Ultra Health Care","PJP":"INVESCO PHARMACEUTICALS ETF","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1"},"translate_title":"加拿大皇家银行表示，Regenxbio 的 RGX-202 似乎“可批准”治疗杜氏肌营养不良症","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FHLC":0.6,"ABBV":1,"IYH":0.6,"VHT":0.6,"MEDX":0.6,"RXL":0.6,"PJP":0.6,"JDOC":0.6,"XLV":0.6,"AGNG":0.6,"TRUH":0.6,"SRPT":1,"GLAM":0.6,"RGNX":1.5,"FTXH":0.6,"IXJ":0.6,"SRPU":0.6,"PPH":0.6},"content_text":"Regenxbio's (RGNX) RGX-202 investigational therapy for Duchenne muscular dystrophy appears \"approvable,\" with safety and function comparable with that of the FDA-approved rival drug from Sarepta Therapeutics (SRPT), RBC Capital Markets said in a Thursday note.The company continues to target biologics license application submission to the US FDA in Q1 2027, with a potential approval in H2 of the same year, RBC said. Regenxbio also designed a randomized trial to back RGX-202's global submissions, the investment firm added.In retinal disease, Regenxbio and partner AbbVie (ABBV) are set to release topline data from two trials of surabgene lomparvovec in wet age-related macular degeneration within this quarter, the brokerage said. Regulatory submissions for the product candidate are planned for 2027, RBC noted.RBC has an outperform rating on Regenxbio, with a $19 price target.Price: 7.75, Change: +0.37, Percent Change: +4.95","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2681189303","isCrawlerRequest":true}